Fig. 5From: Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study GroupQuality-adjusted progression-free-survival based on the EORTC QLQ-C30 Summary score and EORTC Quality of Life Utility Measure-Core 10 dimensions (QLU-C10D). Kd; Carfilzomib-dexamethansoneBack to article page